S. Damian

发表

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

J. Gilbert, D. Day, S. Piha-Paul, 2018, American journal of clinical oncology.

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2018, Breast Cancer Research.

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

J. Machiels, R. Mathijssen, M. D. de Jonge, 2016, Cancer Chemotherapy and Pharmacology.

Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer? Analysis of a Phase II Trial

F. D. De Braud, S. Damian, P. Mariani, 2013, Oncology.

448PDRXDX-101, AN ORAL PAN-TRK, ROS1, AND ALK INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS WITH RELEVANT MOLECULAR ALTERATIONS.

P. David Pearson, A. Isacchi, G. Pelosi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells

V. Mazzaferro, M. Miloso, R. Rigolio, 2021, International journal of molecular sciences.

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

G. Ciliberto, A. Paradiso, F. Baldanti, 2022, Clinical Infectious Diseases.

Alka-372-001: First-in-human, phase I study of entrectinib - an oral pan-trk, ROS1, and ALK inhibitor - in patients with advanced solid tumors with relevant molecular alterations.

G. Pelosi, M. Martignoni, A. Senderowicz, 2015 .

Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.

P. David Pearson, G. Pelosi, M. Martignoni, 2014 .

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

A. Drilon, S. Ou, A. Shaw, 2017, Cancer discovery.

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2018, Breast Cancer Research.

Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples

G. Pruneri, A. Vingiani, F. Perrone, 2022, Exploration of targeted anti-tumor therapy.

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

J. Machiels, F. D. De Braud, M. Tiseo, 2020, Cancers.

Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier.

G. Salles, A. Salar, J. Sancho, 2020, Blood.

Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate.

B. Leyland-Jones, G. Batist, B. Jean-Claude, 1996, Biochemical pharmacology.

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

G. Ciliberto, A. Paradiso, F. Baldanti, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Single Institution trial of anthracycline‐ and taxane‐based chemotherapy for operable breast cancer: The ASTER study

L. Ferrari, S. Cresta, P. Valagussa, 2019, The breast journal.

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies

M. Del Vecchio, S. Cresta, M. Di Nicola, 2019, Cancers.

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

A. Gasbarrini, M. Kudo, J. Bruix, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study

G. Ciliberto, F. Baldanti, G. Apolone, 2022, medRxiv.

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model

S. Manoukian, G. Pruneri, A. Vingiani, 2022, Frontiers in Oncology.

Targeted protein degraders from an oncologist point of view: the Holy Grail of cancer therapy?

S. Cresta, M. Di Nicola, M. Duca, 2021, Critical reviews in oncology/hematology.

Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

G. Apolone, G. Galli, M. Duca, 2022, Therapeutic advances in medical oncology.

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

G. Curigliano, M. Fakih, R. Miceli, 2021, Journal for ImmunoTherapy of Cancer.

Hepatic trans-arterial chemoembolization (TACE) in metastatic breast cancer.

C. Spreafico, S. Cresta, G. Mariani, 2013 .

Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach.

M. Duca, S. Damian, L. Provenzano, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.

G. Apolone, S. Manoukian, G. Pruneri, 2023, JCO precision oncology.

Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project

Katherine E. Honan, S. Fröhling, R. Schlenk, 2023, BMC Cancer.